These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136 [TBL] [Abstract][Full Text] [Related]
24. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004 [TBL] [Abstract][Full Text] [Related]
26. Discovery and application of protein biomarkers for ovarian cancer. Gagnon A; Ye B Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999 [TBL] [Abstract][Full Text] [Related]
27. Screening for ovarian cancer: is it worth the risk? Bell R Nurs Times; 1999 Jan 20-26; 95(3):52-3. PubMed ID: 10076394 [TBL] [Abstract][Full Text] [Related]
28. [Combined use of tumor markers and MRI tomography in differential diagnosis of ovarian neoplasms]. Pavlov SB; Akulina EA; Pavlova GB Klin Med (Mosk); 1999; 77(4):49-51. PubMed ID: 10356919 [TBL] [Abstract][Full Text] [Related]
29. [Tumor markers in epithelial ovarian cancer]. Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857 [TBL] [Abstract][Full Text] [Related]
30. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323 [TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of the Stockholm screening study on ovarian cancer. Einhorn N; Bast R; Knapp R; Nilsson B; Zurawski V; Sjövall K Gynecol Oncol; 2000 Dec; 79(3):466-70. PubMed ID: 11104621 [TBL] [Abstract][Full Text] [Related]
32. [Problem of uterine and ovarian cancer mass screening]. Ohmura M; Oda M Gan To Kagaku Ryoho; 2002 Nov; 29(11):1907-16. PubMed ID: 12465389 [TBL] [Abstract][Full Text] [Related]
33. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters-Engl C; Medl M; Ogris E; Leodolter S Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854 [TBL] [Abstract][Full Text] [Related]
34. Screening for ovarian cancer. Jacobs I; Oram D Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382 [TBL] [Abstract][Full Text] [Related]
35. [Ovarian cancer screening: recommendations for clinical pratice]. Amram-Benamran ML; Cochet S; Petignat P; Sappino AP Rev Med Suisse; 2010 May; 6(250):1062, 1064, 1066-8. PubMed ID: 20564865 [TBL] [Abstract][Full Text] [Related]